Morgan Stanley Downgrades Alkermes (ALKS) to Underweight

(Updated - June 21, 2018 7:18 AM EDT)

(updated to add analyst comment)

Morgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Equalweight to Underweight with a price target of $42.00 (from $67.00).

Analyst David Risinger comments "The trigger for the downgrade is Vivitrol downside risk and our concern that late-stage schizophrenia and depression pipeline candidates could have negative news over the next six months."

an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.

Shares of Alkermes closed at $51.36 yesterday.

You May Also Be Interested In

• HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
• BofA Securities Downgrades International Paper (IP) to Neutral
• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight